Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly for relapsed or refractory AML. Ex vivo drug se...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuusanmäki, Heikki, Kytölä, Sari, Vänttinen, Ida, Ruokoranta, Tanja, Ranta, Amanda, Huuhtanen, Jani, Suvela, Minna, Parsons, Alun, Holopainen, Annasofia, Partanen, Anu, Kuusisto, Milla E.L., Koskela, Sirpa, Räty, Riikka, Itälä-Remes, Maija, Västrik, Imre, Dufva, Olli, Siitonen, Sanna, Porkka, Kimmo, Wennerberg, Krister, Heckman, Caroline A., Ettala, Pia, Pyörälä, Marja, Rimpiläinen, Johanna, Siitonen, Timo, Kontro, Mika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Acute Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316276/
https://www.ncbi.nlm.nih.gov/pubmed/36519325
http://dx.doi.org/10.3324/haematol.2022.281692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316276/
https://www.ncbi.nlm.nih.gov/pubmed/36519325
http://dx.doi.org/10.3324/haematol.2022.281692

Ejemplares similares